Drug Trial Radar · NCT05059262
Study of Vimseltinib for Tenosynovial Giant Cell Tumor
Last checked: Nov 20, 2026Latest source record: Mar 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
123
Actual
Start
Oct 14, 2021
Primary completion
Aug 10, 2023
Study completion Jul 2028
Sponsor
- Lead sponsor
- Deciphera Pharmaceuticals, LLCIndustry
- Sponsor type
- Industry
- First posted
- Sep 28, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter Phase 3 clinical study, which aims to evaluate the effectiveness of an investigational drug called vimseltinib for the treatment of tenosynovial giant cell tumor (TGCT) in cases where surgical removal of the tumor is not an option. The study consists of two parts. In Part 1, eligible study participants will be assigned to receive either vimseltinib or matching placebo for 24 weeks. A number of assessments will be carried out during the course of the study, including physical examinations, blood tests, imaging studies, electrocardiograms, and questionnaires. MRI scans will be used to evaluate the response of the tumors to the treatment. Participants assigned to placebo in Part 1 will have the option to receive vimseltinib for Part 2. Part 2 is a long-term treatment phase in which all participants receive open-label vimseltinib.
Conditions
- Tenosynovial Giant Cell Tumor
- Pigmented Villonodular Synovitis
- Giant Cell Tumor of Tendon Sheath
- Tenosynovial Giant Cell Tumor, Diffuse
- Tenosynovial Giant Cell Tumor, Localized
Interventions
VimseltinibDrug
Administered orally
PlaceboDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) at Week 25 Per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1Time frame: Baseline to Week 25 (Cycle 7, Day 1)
Locations
35 sites in 13 countries. Site status is shown where the registry gives one.
City of Hope
Duarte, California
UC Davis Comprehensive Cancer Center
Sacramento, California
University of Colorado
Aurora, Colorado
University of Kansas
Kansas City, Kansas
Dana Farber Cancer Institute
Boston, Massachusetts
Mayo Clinic Rochester
Rochester, Minnesota
Memorial Sloan-Kettering Cancer Center
New York, New York
Duke Sarcoma Research
Durham, North Carolina
Ohio State University
Columbus, Ohio
University of Texas MD Anderson Cancer Center
Houston, Texas
Seattle Cancer Care Alliance
Seattle, Washington
Chris O'Brien Lifehouse
Camperdown, Australia
McGill University
Montreal, Canada
Princess Margaret Hospital
Toronto, Canada
Institut Bergonié
Bordeaux, France
Centre Léon Bérard
Lyon, France
Institut Gustave Roussy
Villejuif, France
Helios Klinikum Berlin-Buch
Berlin, Germany
University Hospital Essen (Universitätsklinikum Essen)
Essen, Germany
Prince of Wales Hospital
Hong Kong, Hong Kong
Istituto Ortopedico Rizzoli
Bologna, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Naples, Italy
Istituto Oncologico Veneto
Padua, Italy
Istituto Nazionale Tumori Regina Elena
Rome, Italy
Leiden University Medical Center
Leiden, Netherlands
Oslo University Hospital
Oslo, Norway
Klinika Nowotworów Tkanek Miękkich, Kości i Czerniaków Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy
Warsaw, Poland
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
Hospital Universitario Vall d'Hebron
Barcelona, Spain
Fundacion Jimenez Diaz
Madrid, Spain
Hospital Clinico San Carlos
Madrid, Spain
Universitäts-Kinderspital beider Basel (UKBB)
Basel, Switzerland
Cancer & Haematology Centre, The Churchill Hospital - Oxford University Hospitals NHS Foundation Trust
London, United Kingdom
University College London Hospitals
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.